keys 20 Get a Free Trial

Existing client? Login

callout whats new

Miss our Lipid Management Drugs in Development webinar?
Watch recording

callout learn more

Free Intelligence

Intel-based Reports

White Papers

Video Demo

Educational Webinars

Product Brochure

callout newsletter

Email:
Please let us know your email address.

Twitter 16x16Follow us on Twitter

Heard It Here First

BioPharm Insight has been proven to provide subscribers with an information edge by uncovering major stories months or even years before they occur, enabling subscribers to take action before their competitors. Recent examples include:

Threshold Pharmaceuticals Shares Surge on Global Agreement with Merck KGaA

  • We Covered It: June 29, 2011
  • When It Happened: February 3, 2012

Intelligence Edge: 7 months and 5 days

FDA Pulls Avastin's Breast Cancer Approval

  • We Covered It: June 16, 2011
  • When It Happened: November 18, 2011

Intelligence Edge: 5 months and 2 days

Bristol Myers-AstraZeneca Diabetes Drug Dapagliflozin Delayed by U.S. FDA

  • We Covered It: Regulatrory concerns coverage began September 21, 2009
  • When It Happened: November 18, 2011

Intelligence Edge: 2 years, 2 months and 3 days

Evotec AG Terminated the Study of EVT 101 for Treatment-resistant Depression

  • We Covered It: July 27, 2010
  • When It Happened: May 18, 2011

Intelligence Edge: 9 months and 23 days

Exelixis Going Ahead with the Phase III 306 Trial Without a Special Protocol Assessment with the FDA

  • We Covered It: October 25, 2011
  • When It Happened: October 31, 2011

Financial Advantage: Company stock fell ~38% on the news

Begin a Conversation

Contact us to gain an information edge.